Five Prime grants Human Genome Sciences exclusive rights in the U.S., EU, and Canada to cancer candidate FP-1039

Five Prime Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Human Genome Sciences Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$5,277.8m on 03/11/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated